Results 191 to 200 of about 130,425 (315)

The Role of EGFR / KRAS Downstream Targets MEK, EGR1 and KLF5 in Pancreatic Cancer Initiation and Progression [PDF]

, 2015
Thomas von Briel
openalex  

Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

Head &Neck, EarlyView.
ABSTRACT Purpose Olfactory neuroblastoma (ONB) is a rare sinonasal malignancy with limited therapeutic options in the recurrent/metastatic setting; little is known regarding its responsiveness to immunotherapy. Inhibition of enhancer of zeste homolog 2 (EZH2) has been shown to improve T‐cell‐mediated killing and susceptibility to immune checkpoint ...
Elisabetta Xue, Tolulope Adeyelu, Harris Krause, Andrew Elliott, Ranee Mehra, Heloisa Soares, Emil Lou, Ari Vanderwalde, David Spetzler, Dara Bracken‐Clarke, Nyall R. London Jr., James L. Gulley, Charalampos S. Floudas   +12 more
wiley   +1 more source

Molecular Pathology of Advanced NSCLC: Biomarkers and Therapeutic Decisions. [PDF]

Cancers (Basel)
Winter M, Jeroch J, Wetz M, Rauschendorf MA, Wild PJ.   +4 more
europepmc   +1 more source

Statin-dye conjugates for selective targeting of KRAS mutant cancer cells. [PDF]

PLoS One
Moon HR, Cai Z, Cho BK, Chang H, Hong ST, Zhao JJ, Kwon IC, Roberts TM, Han B, Ryu JH.   +9 more
europepmc   +1 more source

Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer [PDF]

, 2016
Ke-Jing Tang, Jerfiz D. Constanzo, Niranjan Venkateswaran, Margherita Melegari, Mariya Ilcheva, Julio C. Morales, Ferdinandos Skoulidis, John V. Heymach, David A. Boothman, Pier Paolo Scaglioni   +9 more
openalex   +1 more source

Alternative splicing of KRAS exon 4 promotes tumor progression via enhanced KRAS4A oncogenic activity. [PDF]

Anim Cells Syst (Seoul)
Cho N, Kwon E, Kim SE, Kim KK.
europepmc   +1 more source

Deciphering allosteric mechanisms in KRAS activation: insights from GTP-induced conformational dynamics and interaction network reorganization

Dongmei Zhao, Jingyu Yang, Meng-Ting Liu, Li-Quan Yang, Peng Sang   +4 more
openalex   +2 more sources

Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial [PDF]

, 2017
E. Martinelli, Claudia Cardone, Teresa Troiani, Nicola Normanno, Salvatore Pisconti, Roberto Bordonaro, Anna Nappi, Francesco Giuliani, M. Biglietto, C. Barone, Anna Maria Rachiglio, Vincenzo Montesarchio, Saverio Cinieri, Daniele Rizzi, Antonio Febbraro, Tiziana Pia Latiano, G. Modoni, G. Colucci, Evaristo Maiello, Fortunato Ciardiello   +19 more
openalex   +1 more source

Intrinsic resistance to RAS inhibitors is driven by dysregulation of KRAS degradation. [PDF]

Nat Commun
Ivanisevic T, Ma Y, Van Boxel E, Magits W, Lechat B, Koçberber Z, Willnow P, Fendt SM, Velde GV, Sewduth R, Sablina AA.   +10 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source